Patents by Inventor Michal Schwartz

Michal Schwartz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10512699
    Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: December 24, 2019
    Assignees: Cedars-Sinai Medical Center, Yeda Research and Development Co., Ltd.
    Inventors: Yosef Koronyo, Maya Koronyo, Keith Black, Michal Schwartz, Daniel L. Farkas
  • Publication number: 20190367623
    Abstract: An active agent that causes an increase in the number of disease-associated microglia (DAM) for use in treating a neurodegenerative disease is provided.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Inventors: Michal SCHWARTZ-EISENBACH, Ido AMIT, Hadas KEREN-SHAUL, Amit SPINRAD, Assaf WEINER, Orit MATCOVITCH NATHAN, Raz DVIR
  • Publication number: 20190022255
    Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.
    Type: Application
    Filed: October 31, 2017
    Publication date: January 24, 2019
    Applicants: Cedars-Sinai Medical Center, Yeda Research and Development, Co., Ltd.
    Inventors: Yosef Koronyo, Maya Koronyo, Keith Black, Michal Schwartz, Daniel L. Farkas
  • Patent number: 10072044
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Grant
    Filed: June 12, 2016
    Date of Patent: September 11, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Schwartz-Eisenbach, Matityahu Fridkin, Michal Cardon-Yaakov
  • Patent number: 9839699
    Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: December 12, 2017
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO., LTD., CEDARS-SINAI MEDICAL CENTER
    Inventors: Yosef Koronyo, Maya Koronyo, Keith L. Black, Michal Schwartz, Daniel L. Farkas
  • Publication number: 20170348393
    Abstract: A method of upregulating an anti-inflammatory response in a central nervous system (CNS) of a subject in need thereof is disclosed. The method comprising locally administering to the CNS of the subject a therapeutically effective amount of IFN-beta, thereby upregulating the anti-inflammatory response in the CNS of the subject. Methods of treating an inflammation in a CNS or treating a disease, disorder, condition or injury of a CNS of a subject are also disclosed.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 7, 2017
    Inventors: Michal SCHWARTZ-EISENBACH, Ido AMIT, Merav COHEN, Orit MATCOVICH
  • Publication number: 20160280739
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: June 12, 2016
    Publication date: September 29, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michal SCHWARTZ-EISENBACH, Matityahu FRIDKIN, Michal CARDON-YAAKOV
  • Publication number: 20150120457
    Abstract: A system and a method for controlling an electronic device embedded in a package of a consumer product are disclosed. In one aspect, the consumer product packaging includes a bottle for a beverage, a memory, a receiver and a circuit. The memory stores an action to be performed in response to an input. The receiver receives the input indicative of movement of the bottle. The circuit retrieves the action stored in memory upon receipt of the input and command an electronic communication module to perform the action at a particular time or in a particular sequence.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: David Philip Miller, Michal Schwartz
  • Publication number: 20130060821
    Abstract: Systems, methods and apparatus are disclosed for database generation of synchronized actions. In one aspect a method is provided for generating a database of data items indicative of synchronized actions. The method includes determining a set of devices for execution of a storyboard. The set of devices includes packaging of a consumer product. The storyboard relates to promotion of the consumer product. The method further includes generating the storyboard. The storyboard includes a set of actions for the devices. The storyboard includes a set of interrelated actions that form a message for communication to an audience. The method further includes generating data items. The data items correspond to the actions of the storyboard. At least a portion of the data items include time synchronization information for the set of actions. The method further includes storing the data items and the time synchronization information relating to the storyboard in the database.
    Type: Application
    Filed: September 5, 2012
    Publication date: March 7, 2013
    Inventors: David Miller, Michal Schwartz
  • Publication number: 20110286932
    Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.
    Type: Application
    Filed: September 18, 2009
    Publication date: November 24, 2011
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO., LTD., CEDARS-SINAI MEDICAL CENTER
    Inventors: Yosef Koronyo, Maya Koronyo, Keith L. Black, Michal Schwartz, Daniel L. Farkas
  • Patent number: 7560100
    Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons. The invention also provides a method of treating a human subject afflicted with a neurodegenerative disease comprising administering to the human subject a therapeutically effective amount of any of the disclosed compositions so as to thereby treat the human subject.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: July 14, 2009
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni
  • Publication number: 20070054857
    Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.
    Type: Application
    Filed: September 29, 2006
    Publication date: March 8, 2007
    Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni
  • Publication number: 20070010484
    Abstract: Oligosaccharides, and in particular disaccharides, which are degradation products of chondroitin sulfate proteoglycan are effective for use in treating, inhibiting, or ameliorating the effects of injuries or diseases or disorders that result in or are caused by neuronal degeneration or of disorders resulting in mental and cognitive dysfunction. They are also useful for promoting neurogenesis.
    Type: Application
    Filed: June 23, 2006
    Publication date: January 11, 2007
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michal Schwartz, Ofer Lider, Asya Rolls, Liora Cahalon, Osnat Lider
  • Publication number: 20060122113
    Abstract: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.
    Type: Application
    Filed: September 9, 2005
    Publication date: June 8, 2006
    Inventors: Irit Pinchasi, Ben-Zion Dolitzky, Anton Frenkel, Michal Schwartz, Ruth Arnon, Rina Aharoni
  • Patent number: 5840295
    Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michal Schwartz, Shoshana Eitan
  • Patent number: 5580555
    Abstract: Administration of tumor necrosis factor to the site of injured central nervous system axons will result in facilitation of the regeneration of axons across the site of the injury. Recombinant human tumor necrosis factor is the preferred substance for such use.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: December 3, 1996
    Assignee: Yeda Research and Development Co. Ltd.
    Inventor: Michal Schwartz